Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
Selective intestinal decontamination with norfloxacin is useful to prevent bacterial infections in several groups of cirrhotic patients at high risk of infection.
However, the emergence of infections caused by Escherichia colt resistant to quinolones has recently been observed in cirrhotic patients undergoing prophylactic norfloxacin.
Our aim is to determine the characteristics of the infections caused by E. colt resistant to norfloxacin in hospitalized cirrhotic patients.
One hundred and six infections caused by E. colt in 99 hospitalized cirrhotic patients were analyzed and distributed into two groups : group I (n=67), infections caused by E. colt sensitive to norfloxacin, and group II (n=39), infections caused by E. colt resistant to norfloxacin.
The clinical and analytical characteristics at diagnosis of the infection were similar in both groups.
Previous prophylaxis with norfloxacin was more frequent in group II (15/67,22.4% vs. 32/39,82%, P<. 0001), as a result of a higher number of patients submitted to continuous long-term prophylaxis in this group, whereas previous short-term prophylaxis was similar in both groups.
Infections were more frequently nosocomial-acquired in group 11 than in group I (17/67,25.3% vs. 20/39,51.2%, P=01).
The type of infections was similar in both groups : urinary tract infections 38 in group I and 24 in group 11, spontaneous bacterial peritonitis 8 and 2, spontaneous bacteremia 4 and 4, and bacterascites 1 and 0, respectively (pNS). (...)
Mots-clés Pascal : Cirrhose, Foie, Chimioprophylaxie, Surinfection, Décontamination, Intestin, Norfloxacine, Antibactérien, Résistance traitement, Escherichia coli, Enterobacteriaceae, Bactérie, Facteur risque, Association morbide, Mortalité, Epidémiologie, Homme, Fluoroquinolone dérivé, Quinolone dérivé, Appareil digestif pathologie, Foie pathologie
Mots-clés Pascal anglais : Cirrhosis, Liver, Chemoprophylaxis, Superinfection, Decontamination, Gut, Norfloxacin, Antibacterial agent, Negative therapeutic reaction, Escherichia coli, Enterobacteriaceae, Bacteria, Risk factor, Concomitant disease, Mortality, Epidemiology, Human, Fluoroquinolone derivatives, Quinolone derivatives, Digestive diseases, Hepatic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0226671
Code Inist : 002B02W. Création : 16/11/1999.